FrankASinicropeMDFACP
Gastroenterology • Rochester, MNGastrointestinal Cancer, Hepatology & Liver Transplantation
Professor, Internal Medicine and Oncology, Mayo Medical School
Dr. Sinicrope is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 1997
University of ChicagoFellowship, Gastroenterology, 1989 - 1992
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1986 - 1988
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1985
Certifications & Licensure
CA State Medical License 1991 - Present
MN State Medical License 2002 - 2025
TX State Medical License 1992 - 2003
IL State Medical License 1985 - 1993- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Start of enrollment: 2004 Feb 01
- Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum Start of enrollment: 2004 Dec 01
- Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer Start of enrollment: 2009 Aug 20
- Join now to see all
Publications & Presentations
PubMed
- 357 citationsEffect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.Steven R. Alberts, Daniel J. Sargent, Suresh G. Nair Md, Michelle R. Mahoney, Margaret M. Mooney
JAMA. 2012-04-04 - 3530 citationsGuidelines for the use and interpretation of assays for monitoring autophagyDaniel J. Klionsky, Fábio Camargo Abdalla, Hagai Abeliovich, Robert T. Abraham, Abraham Acevedo-Arozena
Autophagy. 2012-04-01 - 315 citationsAssociation Between Molecular Subtypes of Colorectal Cancer and Patient SurvivalAmanda I. Phipps, Paul J. Limburg, John A. Baron, Andrea N. Burnett-Hartman, Daniel J. Weisenberger
Gastroenterology. 2015-01-01
Journal Articles
- MiR-139-5p as a Novel Serum Biomarker for Recurrence and Metastasis in Colorectal CancerFrank A Sinicrope, Steven R Alberts, Ajay Goel, Nature
Lectures
- Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).2019 ASCO Annual Meeting - 6/1/2019
- Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repai...2019 ASCO Annual Meeting - 6/1/2019
- Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adju...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Join now to see all
Press Mentions
Mayo Clinic Expert Calls for Public Health Measures to Improve Diet, Reduce Cancer RiskApril 27th, 2022- Tumor Cell PD-L1 May Mediate Sensitivity to Chemotherapy in Colorectal Cancer TreatmentJuly 2nd, 2021
WVU Health System to Manage 203-Bed HospitalDecember 18th, 2020- Join now to see all
Grant Support
- Translational Research In Colon Cancer Prevention &TreatmentNational Cancer Institute2009–2011
- Polyphenon E For The Chemoprevention Of Colorectal CancerNational Cancer Institute2008–2011
- Aberrant Crypt FOCI As A Biomarker For ChemopreventionNational Cancer Institute2006–2009
- Clinical Significance Of Apoptosis In Colon CancerNational Cancer Institute2004–2006
- Clinical Significance Of Apoptosis In Colon CancerNational Cancer Institute2003
- Beta-Catenin And RAR Interact At The PKC Alpha PromoterNational Institute Of Diabetes And Digestive And Kidney Diseases2002
- A Three Arm Phase II Chemoprevention Trial In AdenomatouDivision Of Cancer Prevention And Control1999–2000
- Calcium And Aspirin Prevention TrialNational Cancer Institute1997
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
